<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04217590</url>
  </required_header>
  <id_info>
    <org_study_id>D9485C00001</org_study_id>
    <nct_id>NCT04217590</nct_id>
  </id_info>
  <brief_title>Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects</brief_title>
  <acronym>DIALIZE China</acronym>
  <official_title>A Phase 3b, Multicentre, Prospective, Randomized, Double-Blind, Placebo-Controlled Study to Reduce Incidence of Pre-Dialysis Hyperkalaemia With Sodium Zirconium Cyclosilicate in Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Sodium Zirconium&#xD;
      Cyclosilicate (SZC), as well as the appropriateness of the dosing mechanism, in Chinese&#xD;
      end-stage renal disease (ESRD) patients on chronic haemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, placebo-controlled study to determine the safety and&#xD;
      efficacy of SZC in ESRD subjects with hyperkalaemia and on stable haemodialysis. This study&#xD;
      consists of a screening period, an 8-week randomized treatment period, and a follow-up&#xD;
      period. Approximately 134 stable haemodialysis subjects with persistent pre-dialysis&#xD;
      hyperkalaemia will be enrolled in the study across research sites in China.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Anticipated">December 14, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 14, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects in the following categories during the evaluation period: • maintain a pre-dialysis serum K between 4.0-5.0 mmol/L on 3 out of 4 dialysis treatments following the long interdialytic interval • do not receive rescue therapy</measure>
    <time_frame>Last 4 weeks of the treatment period</time_frame>
    <description>To evaluate the efficacy of SZC as compared to placebo in keeping the S-K concentration between 4.0 and 5.0 mmol/L in subjects on haemodialysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-dialysis S-K values after Short Inter-dialytic Interval (SIDI) and Long Inter-dialytic Interval (LIDI) during the evaluation period</measure>
    <time_frame>Last 4 weeks of the treatment period</time_frame>
    <description>To evaluate the efficacy of SZC as compared to placebo in maintaining the pre-dialysis SK concentration below 5.5 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dialysis S-K values after LIDI during the evaluation period</measure>
    <time_frame>Last 4 weeks of the treatment period</time_frame>
    <description>To evaluate the efficacy of SZC as compared to placebo in maintaining the pre-dialysis LIDI S-K concentration between 5.5 and 3.5 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instances of pre-dialysis after LIDI S-K between 4.0 and 5.0 mmol/L during the evaluation period</measure>
    <time_frame>Last 4 weeks of the treatment period</time_frame>
    <description>To evaluate the efficacy of SZC as compared to placebo with respect to number of predialysis LIDI visits with S-K concentration between 4.0 and 5.0 mmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Instances of potassium gradient of &lt; 3.0 mmol/L after LIDI during the evaluation period</measure>
    <time_frame>Last 4 weeks of the treatment period</time_frame>
    <description>To evaluate the efficacy of SZC as compared to placebo in reducing the potassium gradient to below 3.0 mmol/L</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Hyperkalemia</condition>
  <arm_group>
    <arm_group_label>Sodium Zirconium Cyclosilicate (SZC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Zirconium Cyclosilicate</intervention_name>
    <description>Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of SZC 5g depending on dose level assigned to a patient per non-dialysis days.</description>
    <arm_group_label>Sodium Zirconium Cyclosilicate (SZC)</arm_group_label>
    <other_name>SZC; Lokelma; ZS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated, written informed consent form prior to any mandatory&#xD;
             study specific procedures, sampling, and analyses.&#xD;
&#xD;
          2. Subject must be ≥ 18 years of age inclusive, at the time of signing the informed&#xD;
             consent form.&#xD;
&#xD;
          3. Subjects must have haemodialysis access consisting of an arteriovenous fistula, AV&#xD;
             graft, or tunnelled (permanent) catheter which is expected to remain in place for the&#xD;
             entire duration of the study.&#xD;
&#xD;
          4. Receiving haemodialysis (or hemodiafiltration) 3 times a week for treatment of&#xD;
             end-stage renal disease (ESRD) for at least 3 months before randomization.&#xD;
&#xD;
          5. Pre-dialysis S-K &gt; 5.4 mmol/L after long inter-dialytic interval and &gt; 5.0 mmol/L&#xD;
             after at least one short inter-dialytic interval during screening (as assessed by&#xD;
             central lab).&#xD;
&#xD;
          6. Prescribed dialysate K concentration ≤ 3 mmol/L during screening.&#xD;
&#xD;
          7. Sustained Qb ≥ 200 ml/min and spKt/V ≥ 1.2 (or URR ≥ 63) on stable haemodialysis /&#xD;
             haemodiafltration prescription during screening with prescription (time, dialyzer,&#xD;
             blood flow [Qb], dialysate flow rate [Qd] and bicarbonate concentration) expected to&#xD;
             remain unchanged during study.&#xD;
&#xD;
          8. Subjects must be receiving dietary counselling appropriate for ESRD subjects treated&#xD;
             with haemodialysis / haemodiafiltration as per local guidelines, which includes&#xD;
             dietary potassium restriction.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Myocardial infarction, acute coronary syndrome, stroke, seizure or a thrombotic /&#xD;
             thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism, but excluding&#xD;
             vascular access thrombosis) within 12 weeks prior to randomization.&#xD;
&#xD;
          2. Pseudohyperkalaemia secondary to haemolyzed blood specimen (this situation is not&#xD;
             considered screening failure, sampling or full screening can be postponed to a later&#xD;
             time as applicable).&#xD;
&#xD;
          3. Diagnosis of rhabdomyolysis during the 4 weeks preceding randomization.&#xD;
&#xD;
          4. Presence of cardiac arrhythmias or conduction defects that require immediate&#xD;
             treatment.&#xD;
&#xD;
          5. Any medical condition, including active, clinically significant infection or liver&#xD;
             disease, that in the opinion of the investigator or Sponsor may pose a safety risk to&#xD;
             a subject in this study, which may confound safety or efficacy assessment and&#xD;
             jeopardize the quality of the data, or may interfere with study participation.&#xD;
&#xD;
          6. History of QT prolongation associated with other medications that required&#xD;
             discontinuation of that medication; congenital long QT syndrome or QTc(f) &gt; 550 msec;&#xD;
             uncontrolled atrial fibrillation despite treatment, or asymptomatic sustained&#xD;
             ventricular tachycardia. Subjects with atrial fibrillation controlled by medication or&#xD;
             with transient atrial fibrillation associated with dialysis or peridialytic period are&#xD;
             permitted.&#xD;
&#xD;
          7. Subjects treated with sodium polystyrene sulfonate (e.g. SPS, Kayexalate, Resonium),&#xD;
             calcium polystyrene sulfonate (CPS, Resonium calcium) or patiromer (Veltassa) within 7&#xD;
             days before screening or anticipated in requiring any of these agents during the&#xD;
             study.&#xD;
&#xD;
          8. Participation in another clinical study with an investigational product administered&#xD;
             in the last 1 month before screening.&#xD;
&#xD;
          9. Haemoglobin &lt; 9 g/dL on screening (as assessed on Visit 1).&#xD;
&#xD;
         10. Laboratory diagnosis of hypokalaemia (K &lt; 3.5 mmol/L), hypocalcemia (Ca &lt; 8.2 mg/d or&#xD;
             albumin-corrected Ca &lt; 8.0 mg/dL if the latter is used in local practice),&#xD;
             hypomagnesemia (Mg &lt; 1.7 mg/dL) or severe acidosis (serum bicarbonate 16 mEq/L or&#xD;
             less) in the 4 weeks preceding randomization.&#xD;
&#xD;
         11. Severe leukocytosis (&gt; 20 × 109/L) or thrombocytosis (≥ 450 × 109/L) during screening.&#xD;
&#xD;
         12. Polycythaemia (Hb &gt; 14 g/dL) during screening.&#xD;
&#xD;
         13. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca&#xD;
             staff and/or staff at the study site).&#xD;
&#xD;
         14. Judgment by the investigator that the subject should not participate in the study if&#xD;
             the subject is unlikely to comply with study procedures, restrictions and&#xD;
             requirements.&#xD;
&#xD;
         15. Previous randomisation in the present study.&#xD;
&#xD;
         16. For women only - currently pregnant (confirmed with positive pregnancy test or uterine&#xD;
             ultrasound if pregnancy test is questionable) or breast-feeding.&#xD;
&#xD;
         17. Females of childbearing potential, unless using contraception as detailed in the&#xD;
             protocol or sexual abstinence.&#xD;
&#xD;
         18. Lack of compliance with haemodialysis prescription (both number and duration of&#xD;
             treatments) during the two-week period preceding screening (100% compliance required).&#xD;
&#xD;
         19. Subjects unable to take investigational product drug mix.&#xD;
&#xD;
         20. Scheduled date for living donor kidney transplant.&#xD;
&#xD;
         21. Subjects with a life expectancy of less than 6 months.&#xD;
&#xD;
         22. Known hypersensitivity or previous anaphylaxis to SZC or to components thereof.&#xD;
&#xD;
         23. History of alcohol or drug abuse within 2 years prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhaohui Ni</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Nephrology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, China.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baotou</city>
        <zip>014040</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baotou</city>
        <zip>14010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>100853</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <zip>102206</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dongguan</city>
        <zip>CN-523009</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hangzhou</city>
        <zip>310014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hefei</city>
        <zip>230001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hohhot</city>
        <zip>010017</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jinan</city>
        <zip>250014</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lanzhou</city>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lanzhou</city>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanchang</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <zip>210011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <zip>211112</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ningbo</city>
        <zip>315000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ningbo</city>
        <zip>315010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200065</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200090</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200232</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200233</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>200240</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <zip>201199</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenzhen</city>
        <zip>518035</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenzhen</city>
        <zip>518053</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <zip>300052</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urumchi</city>
        <zip>830054</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Urumqi</city>
        <zip>CN-830004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wenzhou</city>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wenzhou</city>
        <zip>325027</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yangzhou</city>
        <zip>225001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yinchuan</city>
        <zip>750004</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 2, 2020</study_first_submitted>
  <study_first_submitted_qc>January 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 3, 2020</study_first_posted>
  <last_update_submitted>September 10, 2021</last_update_submitted>
  <last_update_submitted_qc>September 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkalemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.&#xD;
All request will be evaluated as per the AZ disclosure commitment:&#xD;
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

